Cost Effectiveness of Pre– vs Post–Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals

Clinical Gastroenterology and Hepatology

Volumn 16, Issue 1, 2018, Pages 115-122.e10

  Samur, Sumeyye ^a,b   Kues, Brian ^c   Ayer, Turgay ^c   Roberts, Mark S ^d,e   Kanwal, Fasiha ^f,g   Hur, Chin ^a,b   Donnell, Drew Michael S ^d,e   Chung, Raymond T ^a,b   Chhatwal, Jagpreet ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Georgia Institute of Technology   (Georgia)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Health Economics; Simulation Model; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SOFOSBUVIR; UNCLASSIFIED DRUG;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG COST; HEALTH CARE COST; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; LIFE EXPECTANCY; LIVER GRAFT; LIVER GRAFT REJECTION; LONG TERM CARE; MATHEMATICAL ANALYSIS; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGED; CHRONIC HEPATITIS C; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GRAFT RECIPIENT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; THEORETICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIFE EXPECTANCY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 85038264786     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.06.024     Document Type: Article

References (41)

1. Rosen, H.R., Chronic hepatitis C infection. N Engl J Med 364 (2011), 2429–2438.
2. Bunchorntavakul, C., Reddy, K.R., Management of hepatitis C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J Clin Transl Hepatol 2 (2014), 124–133.
3. Roche, B., Samuel, D., Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 32 (2012), 120–128.
4. Curry, M.P., Forns, X., Chung, R.T., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107.e101.
5. Carrion, A.F., Khaderi, S.A., Sussman, N.L., Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation. Liver Transplant 22 (2016), 279–280.
6. Canary, L.A., Klevens, R., Holmberg, S.D., Limited access to new hepatitis c virus treatment under state Medicaid programs. Ann Intern Med 163 (2015), 226–228.
7. Ahmed, A., Gonzalez, S.A., Cholankeril, G., et al. Treatment of patients waitlisted for liver transplant with an all-oral DAAs is a cost-effective treatment strategy in the United States. Hepatology 66 (2017), 46–56.
8. Tapper, E.B., Hughes, M.S., Buti, M., et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C cirrhosis: a cost-effectiveness analysis. Transplantation 101 (2017), 987–995.
9. Njei, B., McCarty, T.R., Fortune, B.E., et al. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther 44 (2016), 1090–1101.
10. Chhatwal, J., Samur, S., Kues, B., et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology 65 (2017), 777–788.
11. Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
12. Manns, M., Samuel, D., Gane, E.J., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16 (2016), 685–697.
13. Gane E, Manns M, McCaughan G, et al. Ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: SOLAR-1 and -2 trials (abstr 1049). In: Liver Meeting 2015, San Francisco, California.
14. Shechter, S.M., Bryce, C.L., Alagoz, O., et al. A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making 25 (2005), 199–209.
15. Alagoz, O., Maillart, L.M., Schaefer, A.J., et al. The optimal timing of living-donor liver transplantation. Manage Sci 50 (2004), 1420–1430.
16. Massie, A.B., Caffo, B., Gentry, S.E., et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 11 (2011), 2362–2371.
17. Lai, J.C., O'Leary, J.G., Trotter, J.F., et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 18 (2012), 532–538.
18. Saab, S., Hunt, D.R., Stone, M.A., et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 16 (2010), 748–759.
19. McAdam-Marx, C., McGarry, L.J., Hane, C.A., et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 17 (2011), 531–546.
20. RedBook Online 2014 Available from: http://www.redbook.com/redbook/online/. Accessed: November 10, 2015.
21. Chhatwal, J., Kanwal, F., Roberts, M.S., et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162 (2015), 397–406.
22. Thompson Coon, J., Rogers, G., Hewson, P., et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 98 (2008), 1166–1175.
23. Chong, C.A.K.Y., Gulamhussein, A., Heathcote, E.J., et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 98 (2003), 630–638.
24. Belli, L.S., Berenguer, M., Cortesi, P.A., et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 65 (2016), 524–531.
25. Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
26. Manns, M., Samuel, D., Gane, E.J., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16 (2016), 685–697.
27. Gane E, Manns M, McCaughan G, et al, eds. Ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: SOLAR-1 and -2 trials (abstr 1049). AASLD 2015.
28. Alagoz, O., Maillart, L.M., Schaefer, A.J., et al. The optimal timing of living-donor liver transplantation. Manage Sci 50 (2004), 1420–1430.
29. Massie, A.B., Caffo, B., Gentry, S.E., et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 11 (2011), 2362–2371.
30. Thuluvath, P., Guidinger, M., Fung, J., et al. Liver transplantation in the United States, 1999–2008. Am J Transplant 10 (2010), 1003–1019.
31. Berenguer, M., Prieto, M., San Juan, F., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36 (2002), 202–210.
32. Berenguer, M., Prieto, M., Rayon, J.M., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32 (2000), 852–858.
33. Samuel, D., Feray, C., Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat 7 (2000), 87–92.
34. Lai, J.C., O'Leary, J.G., Trotter, J.F., et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 18 (2012), 532–538.
35. Chong, C.A., Gulamhussein, A., Heathcote, E.J., et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 98 (2003), 630–638.
36. Chhatwal, J., Kanwal, F., Roberts, M.S., et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162 (2015), 397–406.
37. Thompson Coon, J., Rogers, G., Hewson, P., et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 98 (2008), 1166–1175.
38. RedBook online 2014. Available from: http://www.redbook.com/redbook/online/. Accessed: November 10, 2015.
39. McAdam-Marx, C., McGarry, L.J., Hane, C.A., et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 17 (2011), 531–546.
40. Saab, S., Hunt, D.R., Stone, M.A., et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 16 (2010), 748–759.
41. Hanmer, J., Lawrence, W.F., Anderson, J.P., et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 26 (2006), 391–400.